These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 27746291)

  • 1. Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience.
    Pose E; Solà E; Piano S; Gola E; Graupera I; Guevara M; Cárdenas A; Angeli P; Ginès P
    Am J Med; 2017 Mar; 130(3):372-375. PubMed ID: 27746291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia.
    Hayashi M; Abe K; Fujita M; Okai K; Takahashi A; Ohira H
    Intern Med; 2018 Sep; 57(17):2451-2458. PubMed ID: 29607963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current options of treatment of hyponatremia].
    Tesař V
    Vnitr Lek; 2016; 62 Suppl 6():97-101. PubMed ID: 28124939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility and safety of tolvaptan in cirrhotic patients with hyponatremia: A prospective cohort study.
    Jia JD; Xie W; Ding HG; Mao H; Guo H; Li Y; Wang X; Wang JF; Lu W; Li CZ; Mao Y; Wang GQ; Gao YQ; Wang B; Zhang Q; Ge Y; Wong VW
    Ann Hepatol; 2017; 16(1):123-132. PubMed ID: 28051801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.
    Kogiso T; Kobayashi M; Yamamoto K; Ikarashi Y; Kodama K; Taniai M; Torii N; Hashimoto E; Tokushige K
    Intern Med; 2017 Nov; 56(22):2993-3001. PubMed ID: 28943585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolvaptan treatment improves survival of cirrhotic patients with ascites and hyponatremia.
    Wang S; Zhang X; Han T; Xie W; Li Y; Ma H; Liebe R; Weng H; Ding HG
    BMC Gastroenterol; 2018 Sep; 18(1):137. PubMed ID: 30180806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients.
    Zhang X; Wang SZ; Zheng JF; Zhao WM; Li P; Fan CL; Li B; Dong PL; Li L; Ding HG
    World J Gastroenterol; 2014 Aug; 20(32):11400-5. PubMed ID: 25170228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of tolvaptan in patients hospitalized for worsening chronic heart failure with severe hyponatremia: The initial experience at a single-center in Turkey.
    Sağ S; Aydın Kaderli A; Yıldız A; Gül BC; Özdemir B; Baran İ; Güllülü S; Aydınlar A; Çavuşoğlu Y
    Turk Kardiyol Dern Ars; 2017 Jul; 45(5):415-425. PubMed ID: 28694395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypervolemic Hyponatremia (Liver).
    Solà E; Ginès P
    Front Horm Res; 2019; 52():104-112. PubMed ID: 32097916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis.
    Cárdenas A; Ginès P; Marotta P; Czerwiec F; Oyuang J; Guevara M; Afdhal NH
    J Hepatol; 2012 Mar; 56(3):571-8. PubMed ID: 22027579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolvaptan and Neurocognitive Function in Mild to Moderate Chronic Hyponatremia: A Randomized Trial (INSIGHT).
    Verbalis JG; Ellison H; Hobart M; Krasa H; Ouyang J; Czerwiec FS;
    Am J Kidney Dis; 2016 Jun; 67(6):893-901. PubMed ID: 26874645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.
    Gaglio P; Marfo K; Chiodo J
    Dig Dis Sci; 2012 Nov; 57(11):2774-85. PubMed ID: 22732834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vasopressin receptor antagonists: the vaptans].
    Villabona C
    Endocrinol Nutr; 2010 May; 57 Suppl 2():41-52. PubMed ID: 21130961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia.
    Dahl E; Gluud LL; Kimer N; Krag A
    Aliment Pharmacol Ther; 2012 Oct; 36(7):619-26. PubMed ID: 22908905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical review: the use of vaptans in clinical endocrinology.
    Peri A
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1321-32. PubMed ID: 23401044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Tolvaptan in the Perioperative Management of Severe Hyponatremia During Liver Transplantation: A Case Report.
    Parekh A; Rajaram P; Patel G; Subramanian RM
    Transplant Proc; 2017 Dec; 49(10):2399-2401. PubMed ID: 29198689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.